Rolimus 10mg

Rolimus 10 is a medication used to treat various types of cancer, including kidney, breast, and pancreatic cancer. It is an oral medication that works by inhibiting the activity of a protein called mTOR, which is involved in the growth and survival of cancer cells.

Composition:

Rolimus 10 contains Everolimus, a medication that is a derivative of rapamycin.

Indications:

Rolimus 10 is indicated for the treatment of:

1. Renal cell carcinoma (kidney cancer) that has spread to other parts of the body
2. Breast cancer that has spread to other parts of the body
3. Pancreatic neuroendocrine tumors (PNETs)
4. Other types of cancer, including lymphangioleiomyomatosis (LAM) and progressive multiple sclerosis

Mechanism of Action:

Everolimus works by:

1. Inhibiting the activity of mTOR, which is a protein that plays a key role in the regulation of cell growth and proliferation
2. Inhibiting the activity of other proteins that are involved in the growth and survival of cancer cells

Dosage and Administration: The recommended dosage of Rolimus 10 is:

• 10mg taken orally once daily, with or without food
• The dose should be taken at the same time each day
• The medication should be taken continuously until disease progression or unacceptable toxicity

Side Effects:

Common side effects of Rolimus 10 include:

1. Stomatitis (mouth sores)
2. Diarrhea
3. Fatigue
4. Rash
5. Nausea and vomiting
6. Abdominal pain

Serious side effects can include:

1. Severe allergic reactions
2. Hematological toxicity (reduced bone marrow function)
3. Liver damage
4. Pancreatitis (inflammation of the pancreas)
5. Pneumonitis (inflammation of the lungs)

Contraindications:

Rolimus 10 is contraindicated in patients with:

1. Hypersensitivity to Everolimus
2. Severe liver or kidney disease
3. Pregnancy or breastfeeding

Precautions:

1. Patients with a history of liver or kidney disease should be closely monitored while receiving Rolimus 10.
2. Patients with a history of severe allergic reactions should be closely monitored while receiving Rolimus 10.
3. Patients with a history of respiratory disease should be closely monitored while receiving Rolimus 10.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of mouth sores or diarrhea.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.